Lilly, Insilico partner on AI drug development

Eli Lilly and Insilico Medicine have entered into a significant collaboration focused on leveraging artificial intelligence for drug discovery. This partnership could be worth as much as $2.75 billion, highlighting the increasing integration of AI in the pharmaceutical sector. The deal underscores the potential for AI to accelerate the identification and development of new therapies, promising faster innovation and potentially more effective treatments for various diseases.